Despite the pleiotropy of the Rac1-driven resistance pathways, we identified focal adhesion kinase (FAK) inhibition as a promising strategy for the treatment of Rac1-driven drug-resistance in melanoma. The gene discussed is PTK2; the disease is melanoma.